Success Metrics

Clinical Success Rate
100.0%

Based on 18 completed trials

Completion Rate
100%(18/18)
Active Trials
4(13%)
Results Posted
11%(2 trials)

Phase Distribution

Ph phase_3
1
3%
Ph not_applicable
3
10%
Ph phase_1
1
3%
Ph phase_4
26
84%

Phase Distribution

1

Early Stage

0

Mid Stage

27

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
1(3.2%)
Phase 3Large-scale testing
1(3.2%)
Phase 4Post-market surveillance
26(83.9%)
N/ANon-phased studies
3(9.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

18 of 18 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

31

all time

Status Distribution
Active(5)
Completed(18)
Other(8)

Detailed Status

Completed18
unknown8
Recruiting3
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
31
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (3.2%)
Phase 31 (3.2%)
Phase 426 (83.9%)
N/A3 (9.7%)

Trials by Status

completed1858%
recruiting310%
unknown826%
not_yet_recruiting13%
active_not_recruiting13%

Recent Activity

Clinical Trials (31)

Showing 20 of 31 trialsScroll for more
NCT06561711Phase 4

Optimization of Minocycline for Helicobacter Pylori Rescue Treatment

Completed
NCT05874544Phase 4

Rescue Therapy for Helicobacter Pylori Infection

Completed
NCT06523764Phase 4

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

Active Not Recruiting
NCT05874570Phase 4

Doxycycline for Helicobacter Pylori Rescue Treatment

Recruiting
NCT04531059Phase 4

Rescue Therapy for Helicobacter Pylori Eradication Treatment

Completed
NCT06561698Phase 4

High-dose Dual Therapy and Minocycline-cotaining Quadruple Therapy for Helicobacter Pylori Infection

Recruiting
NCT05431075Phase 4

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Completed
NCT04198363Phase 3

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Completed
NCT04753437Phase 1

A Study of Vonoprazan in Adults With Helicobacter Pylori

Completed
NCT05049902Phase 4

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Completed
NCT05726734Phase 4

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Not Yet Recruiting
NCT04879992Not Applicable

Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

Completed
NCT05189444Not Applicable

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

Unknown
NCT05250050Phase 4

Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment

Unknown
NCT03688828Not Applicable

Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Completed
NCT05061732Phase 4

Helicobacter Pylori Eradication and Follow-up

Recruiting
NCT05023577Phase 4

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

Unknown
NCT05018923Phase 4

Tetracycline Versus Doxycycline for HP Rescue Therapy

Unknown
NCT05014685Phase 4

PPI-amoxicillin for H. Pylori Treatment

Unknown
NCT04901117Phase 4

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
31